Kidney disease secondary to T2DM and obesity demonstrates similar pathogenesis, with long-term decreases in glomerular filtration rate (GFR), nephrosclerosis, and progression to end-stage renal disease, where GLP-1 receptor agonist (GLP-1RA) treatment slows CKD progression, measured by an attenuated decline in GFR in patients with either T2DM or obesity and CKD [12,13]. Here, GLP1R is linked to obesity disorder.